Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3811 in Pathological Scar
NCT07576608Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 9MW3811 in Pathological scar, sponsored by Mabwell. Started Dec 2025; status: recruiting.
02
Drugs
9MW3811
03
Conditions
Pathological scar
Beyond the preview
Go deeper on NCT07576608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576608.